Angiographic pattern of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation different to that after bare metal stent (BMS), but their subsequent TLR rate was similar to both types of DES.
Drug-eluting stents (DES) have gained widespread adoption being implanted in over 6 million patients worldwide demonstrating significant improvements in clinical efficacy combined with comparable safety to bare metal stents.
An investigational drug-eluting stent called Xience, coated with everolimus, led to significantly less late lumen loss after nine months than did the Taxus (paclitaxel-eluting) stent, said researchers here today. March 2007
An investigational bioabsorbable coronary artery stent, in its first human trials, showed acceptable safety, with efficacy better than bare-metal devices but well short of drug-eluting devices, Dutch researchers said here.
Martin Leon, M.D., a leading interventional cardiologist accused of leaking details of a major study weeks before its scheduled release, was barred today from taking part in next year's American College of Cardiology meeting.
An investigational bioabsorbable magnesium coronary stent worked as advertised for several months but led to a higher revascularization rate at one year.
In much of the world (but not in the U.S.,) drug-coated stents are avoided by cardiologists because of their high cost. To compensate for the inability to use these stents, many cardiologists outside of the U.S. have taken to administering sirolimus (also
In the Injury Theory, it's damage to the arterial endothelium, followed by platelet activation, then smooth muscle cell migration to injury, then macrophages, with resulting "foam cells." Engorged foam cells burst, starting the injury cycle all over again
it may no longer be enough to measure just HDL levels without determining levels of paroxonase and platelet-activating acetylhydrolase; levels of these enzymes may determine whether HDL is proinflammatory or protective. Likewise, measuring Lp(a) and small
Overweight men and women assigned to drink fructose-sweetened beverages as 25% of their energy intake developed atherogenic lipid profiles in just two weeks; unlike glucose, fructose promotedatherogenic lioproprotein phenotypes and glucose intolerance/ins